Transplant Survival after Berlin Heart EXCOR Support

Roosevelt Bryant, Farhan Zafar, Chesney Castleberry, John Jefferies, Angela Lorts, Clifford Chin, David L.S. Morales

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The Berlin Heart EXCOR pediatric ventricular assist device (VAD) is approved by the Food and Drug Administration for bridge to cardiac transplantation (BTT) in children. As the clinical outcomes of the EXCOR continue to be evaluated in the United States, data on post-transplant survival are needed. The UNOS database was used to identify patients <18 years old undergoing orthotopic heart transplantation (OHT) from June 2004 to June 2014. Patients undergoing BTT with the EXCOR were identified. A matched cohort of (358) patients undergoing OHT without pretransplant mechanical circulatory support (no-MCS) was also identified as control subjects. The post-transplant survival between the two groups was compared. There were 2,885 pediatric OHT during the study period. Of these, 358 (50%) patients were BTT with the EXCOR. At time of listing, inotrope use was 51.7% vs. 53.4%, (p = 0.653) in the EXCOR cohort and the no-MCS cohort, respectively. At the time of transplantation, end-organ function was equivalent with same median creatinine levels (0.4, p = 0.203) and median total bilirubin (0.5, p = 0.682) for the EXCOR and the no-MCS cohorts. Kaplan-Meier post-transplantation survival did not differ between the two cohorts (30 day, 1 year, and 5 year post-transplant survival was 94%, 90%, and 72% [EXCOR cohort] vs. 98%, 91%, and 77% [no-MCS cohort]; p = 0.160). Short- and mid-term post-transplant survival using the EXCOR Pediatric VAD as a BTT in children is equivalent to patients who underwent OHT without pretransplant MCS.

Original languageEnglish (US)
Pages (from-to)80-85
Number of pages6
JournalASAIO Journal
Volume63
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Transplants
Berlin
Heart Transplantation
Pediatrics
Heart-Assist Devices
Bilirubin
Creatinine
Organ Transplantation
United States Food and Drug Administration
Transplantation
Databases
Survival

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Bioengineering
  • Biomaterials
  • Biomedical Engineering

Cite this

Bryant, R., Zafar, F., Castleberry, C., Jefferies, J., Lorts, A., Chin, C., & Morales, D. L. S. (2017). Transplant Survival after Berlin Heart EXCOR Support. ASAIO Journal, 63(1), 80-85. https://doi.org/10.1097/MAT.0000000000000439

Transplant Survival after Berlin Heart EXCOR Support. / Bryant, Roosevelt; Zafar, Farhan; Castleberry, Chesney; Jefferies, John; Lorts, Angela; Chin, Clifford; Morales, David L.S.

In: ASAIO Journal, Vol. 63, No. 1, 01.01.2017, p. 80-85.

Research output: Contribution to journalArticle

Bryant, R, Zafar, F, Castleberry, C, Jefferies, J, Lorts, A, Chin, C & Morales, DLS 2017, 'Transplant Survival after Berlin Heart EXCOR Support', ASAIO Journal, vol. 63, no. 1, pp. 80-85. https://doi.org/10.1097/MAT.0000000000000439
Bryant R, Zafar F, Castleberry C, Jefferies J, Lorts A, Chin C et al. Transplant Survival after Berlin Heart EXCOR Support. ASAIO Journal. 2017 Jan 1;63(1):80-85. https://doi.org/10.1097/MAT.0000000000000439
Bryant, Roosevelt ; Zafar, Farhan ; Castleberry, Chesney ; Jefferies, John ; Lorts, Angela ; Chin, Clifford ; Morales, David L.S. / Transplant Survival after Berlin Heart EXCOR Support. In: ASAIO Journal. 2017 ; Vol. 63, No. 1. pp. 80-85.
@article{96cd2f42e0ea4f13be738b416bf4a74c,
title = "Transplant Survival after Berlin Heart EXCOR Support",
abstract = "The Berlin Heart EXCOR pediatric ventricular assist device (VAD) is approved by the Food and Drug Administration for bridge to cardiac transplantation (BTT) in children. As the clinical outcomes of the EXCOR continue to be evaluated in the United States, data on post-transplant survival are needed. The UNOS database was used to identify patients <18 years old undergoing orthotopic heart transplantation (OHT) from June 2004 to June 2014. Patients undergoing BTT with the EXCOR were identified. A matched cohort of (358) patients undergoing OHT without pretransplant mechanical circulatory support (no-MCS) was also identified as control subjects. The post-transplant survival between the two groups was compared. There were 2,885 pediatric OHT during the study period. Of these, 358 (50{\%}) patients were BTT with the EXCOR. At time of listing, inotrope use was 51.7{\%} vs. 53.4{\%}, (p = 0.653) in the EXCOR cohort and the no-MCS cohort, respectively. At the time of transplantation, end-organ function was equivalent with same median creatinine levels (0.4, p = 0.203) and median total bilirubin (0.5, p = 0.682) for the EXCOR and the no-MCS cohorts. Kaplan-Meier post-transplantation survival did not differ between the two cohorts (30 day, 1 year, and 5 year post-transplant survival was 94{\%}, 90{\%}, and 72{\%} [EXCOR cohort] vs. 98{\%}, 91{\%}, and 77{\%} [no-MCS cohort]; p = 0.160). Short- and mid-term post-transplant survival using the EXCOR Pediatric VAD as a BTT in children is equivalent to patients who underwent OHT without pretransplant MCS.",
author = "Roosevelt Bryant and Farhan Zafar and Chesney Castleberry and John Jefferies and Angela Lorts and Clifford Chin and Morales, {David L.S.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/MAT.0000000000000439",
language = "English (US)",
volume = "63",
pages = "80--85",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Transplant Survival after Berlin Heart EXCOR Support

AU - Bryant, Roosevelt

AU - Zafar, Farhan

AU - Castleberry, Chesney

AU - Jefferies, John

AU - Lorts, Angela

AU - Chin, Clifford

AU - Morales, David L.S.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The Berlin Heart EXCOR pediatric ventricular assist device (VAD) is approved by the Food and Drug Administration for bridge to cardiac transplantation (BTT) in children. As the clinical outcomes of the EXCOR continue to be evaluated in the United States, data on post-transplant survival are needed. The UNOS database was used to identify patients <18 years old undergoing orthotopic heart transplantation (OHT) from June 2004 to June 2014. Patients undergoing BTT with the EXCOR were identified. A matched cohort of (358) patients undergoing OHT without pretransplant mechanical circulatory support (no-MCS) was also identified as control subjects. The post-transplant survival between the two groups was compared. There were 2,885 pediatric OHT during the study period. Of these, 358 (50%) patients were BTT with the EXCOR. At time of listing, inotrope use was 51.7% vs. 53.4%, (p = 0.653) in the EXCOR cohort and the no-MCS cohort, respectively. At the time of transplantation, end-organ function was equivalent with same median creatinine levels (0.4, p = 0.203) and median total bilirubin (0.5, p = 0.682) for the EXCOR and the no-MCS cohorts. Kaplan-Meier post-transplantation survival did not differ between the two cohorts (30 day, 1 year, and 5 year post-transplant survival was 94%, 90%, and 72% [EXCOR cohort] vs. 98%, 91%, and 77% [no-MCS cohort]; p = 0.160). Short- and mid-term post-transplant survival using the EXCOR Pediatric VAD as a BTT in children is equivalent to patients who underwent OHT without pretransplant MCS.

AB - The Berlin Heart EXCOR pediatric ventricular assist device (VAD) is approved by the Food and Drug Administration for bridge to cardiac transplantation (BTT) in children. As the clinical outcomes of the EXCOR continue to be evaluated in the United States, data on post-transplant survival are needed. The UNOS database was used to identify patients <18 years old undergoing orthotopic heart transplantation (OHT) from June 2004 to June 2014. Patients undergoing BTT with the EXCOR were identified. A matched cohort of (358) patients undergoing OHT without pretransplant mechanical circulatory support (no-MCS) was also identified as control subjects. The post-transplant survival between the two groups was compared. There were 2,885 pediatric OHT during the study period. Of these, 358 (50%) patients were BTT with the EXCOR. At time of listing, inotrope use was 51.7% vs. 53.4%, (p = 0.653) in the EXCOR cohort and the no-MCS cohort, respectively. At the time of transplantation, end-organ function was equivalent with same median creatinine levels (0.4, p = 0.203) and median total bilirubin (0.5, p = 0.682) for the EXCOR and the no-MCS cohorts. Kaplan-Meier post-transplantation survival did not differ between the two cohorts (30 day, 1 year, and 5 year post-transplant survival was 94%, 90%, and 72% [EXCOR cohort] vs. 98%, 91%, and 77% [no-MCS cohort]; p = 0.160). Short- and mid-term post-transplant survival using the EXCOR Pediatric VAD as a BTT in children is equivalent to patients who underwent OHT without pretransplant MCS.

UR - http://www.scopus.com/inward/record.url?scp=84988662686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988662686&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000439

DO - 10.1097/MAT.0000000000000439

M3 - Article

VL - 63

SP - 80

EP - 85

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 1

ER -